Stockscreener 앱 받기
26.85
2.96%
-0.82
시간 외 거래:
26.85
전일 마감가:
$27.67
열려 있는:
$27.21
하루 거래량:
477.33K
Relative Volume:
0.63
시가총액:
$1.30B
수익:
$458.69M
순이익/손실:
$11.68M
주가수익비율:
111.78
EPS:
0.2402
순현금흐름:
$14.58M
1주 성능:
+6.21%
1개월 성능:
+19.49%
6개월 성능:
-34.14%
1년 성능:
-13.13%
1일 변동 폭
$26.61
$27.56
1주일 범위
$25.56
$28.03
52주 변동 폭
$19.16
$48.25
Artivion Inc Stock (AORT) Company Profile
명칭
Artivion Inc
전화
(770) 419-3355
주소
1655 ROBERTS BOULEVARD N W, KENNESAW
Compare AORT vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
26.85 | 1.27B | 458.69M | 11.68M | 14.58M | 0.2402 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2025-08-13 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2025-06-17 | 개시 | Canaccord Genuity | Buy |
| 2024-10-23 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-27 | 재확인 | Lake Street | Buy |
| 2022-08-08 | 개시 | Lake Street | Buy |
| 2022-03-03 | 개시 | Stifel | Buy |
모두보기
Artivion Inc 주식(AORT)의 최신 뉴스
Artivion Inc (AORT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Artivion Market Sentiment - Benzinga España
Artivion Inc (AORT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Artivion Inc (AORT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AORT|Artivion Inc|Price:25.280|Chg%:+0.280 - TradingKey
Artivion Inc (AORT) Balance Sheet - TradingKey
Artivion, Inc. Revenue Breakdown – SWB:CYL - TradingView
AORT|Artivion Inc|Price:26.100|Chg%:+0.820 - TradingKey
Artivion, Inc. (AORT) stock price, news, quote and history - Yahoo Finance UK
Artivion, Inc. Revenue Breakdown – LS:900006 - TradingView
Artivion Inc (AORT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Artivion schedules Q2 results webcast for Aug. 6 at 4:30 p.m. - Stock Titan
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results - TradingView
Artivion Inc (AORT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Artivion (AORT) Grew in Q1, but AMDS Timing and Lower 2026 Targets Still Softened the Story - AlphaStreet
Below Expected Sales for AMDS Hurt Artivion (AORT) in Q2 - Yahoo Finance
Citizens reiterates Artivion stock rating citing FDA approval benefits By Investing.com - Investing.com South Africa
Citizens reiterates Artivion stock rating citing FDA approval benefits - Investing.com
Needham reiterates Artivion stock rating on product cycle outlook By Investing.com - Investing.com Nigeria
Needham reiterates Artivion stock rating on product cycle outlook - Investing.com
Artivion (AORT) Corporate presentation Summary - Quartr
Artivion, Inc. (AORT) Stock Live Price, Chart & News - CoinCodex
Artivion, Inc. (AORT) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
AORT Q1 2026 Earnings: EPS Misses Estimates, Stock Edges LowerDividend Growth Analysis - Bölüm Sonu Canavarı
Artivion (AORT) Stifel 2025 Healthcare Conference Summary - Quartr
Artivion (AORT) Is Up 10.1% After Full FDA PMA Approval for AMDS Aortic Device - simplywall.st
What Boosted Artivion (NYSE:AORT) Following FDA PMA Approval? - Kalkine Media
Artivion seeks to tap $150 million US market opportunity with FDA approval - MSN
Artivion stock gets FDA approval for NEXUS stent graft system By Investing.com - Investing.com India
Artivion (AORT) Stock Forum and Discussion - Moomoo
AORTArtivion Inc Options - Finviz
Artivion raises 2025 revenue guidance to $435M–$443M as On-X and stent grafts drive double-digit growth - MSN
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device - Yahoo Finance
Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion (NYSE:AORT) - Seeking Alpha
Artivion stock rises after FDA approves AMDS device - Investing.com
Enterprise value to revenue forward of Artivion, Inc. – SWB:CYL - TradingView
Canaccord reiterates Artivion stock rating on FDA approval By Investing.com - Investing.com South Africa
Artivion (AORT) Secures FDA Approval for AMDS Hybrid Prosthesis - GuruFocus
Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval - Benzinga
Why Artivion (AORT) Is Up 17.3% After Full FDA PMA Approval for AMDS Hybrid Prosthesis - simplywall.st
Artivion receives FDA PMA approval for AMDS Hybrid Prosthesis in aortic dissections - grafa.com
Canaccord reiterates Artivion stock rating on FDA approval - Investing.com
Artivion Shares Rise After FDA Approves AMDS Aortic Device - TradingPedia
Artivion Wins FDA Nod for AMDS Hybrid Prosthesis - Medical Product Outsourcing
Artivion stock rises after FDA approves AMDS device By Investing.com - Investing.com Canada
Artivion, Inc.(NYSE: AORT) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Artivion's Hybrid Prosthesis Device Gets FDA Premarket Approval; Shares Up Pre-Bell - Moomoo
Artivion receives FDA approval for aortic dissection device By Investing.com - Investing.com South Africa
Artivion receives FDA approval for aortic dissection device - Investing.com
Artivion Inc (AORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Artivion Inc 주식 (AORT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GREEN ANDREW M | SVP, Regulatory and Quality |
Jun 11 '26 |
Sale |
20.70 |
44,001 |
910,739 |
60,259 |
1.04%
11.95%
자본화:
|
볼륨(24시간):